Zusammenfassung
Hintergrund
Die Bestimmung einer HER2/neu-Überexpression im Gewebe eines Mammakarzinoms gibt Aufschluss über einen wichtigen prognostischen und prädiktiven Marker. Eine Überexpression von HER2/neu ist beim Mammakarzinom mit einer schlechten Prognose assoziiert. Da die Nadelbiopsie zunehmend in der Diagnostik des Mammakarzinoms angewandt wird, war es unser Ziel die Zuverlässigkeit der HER2/neu-Bestimmung in der Nadelbiopsie bei Patientinnen mit primärem Mammakarzinom zu evaluieren.
Patienten und Methoden
Wir untersuchten an 325 Patientinnen mit primärem Mammakarzinom die Genauigkeit der immunhistochemischen HER2/neu-Bestimmung in der Nadelbiopsie verglichen mit dem Operationspräparat. Bei Patientinnen mit stark positivem HER2/neu Status wurde zusätzlich eine Fluoreszenz in situ Hybridisierung (FISH) der Nadelbiopsie durchgeführt.
Ergebnisse
Die Genauigkeit der HER2/neu-Bestimmung in der Nadelbiopsie verglichen mit dem Operationspräparat durch Immunhistochemie alleine war 92% und konnte durch zusätzliche FISH Analyse auf 96% und werden (gewichteter Kappa Koeffizient: 0,86).
Diskussion
Wir konnten an diesem großen Patientenkollektiv zeigen, dass die Bestimmung von HER2/neu in der Nadelbiopsie beim Mammakarzinom verlässlich ist. Bei immunhistochemisch stark positivem HER2/neu Status in der Nadelbiopsie sollte dies durch FISH überprüft werden, um die Zahl der falsch positiven Ergebnisse zu minimieren.
Summary
Introduction
The assessment of HER2/neu overexpression in tissue provides information about one of the most relevant prognostic and predictive markers in breast cancer: overexpression of HER2/neu is associated with worse prognosis in primary breast cancer. Since core needle biopsy is increasingly used for the diagnosis of breast cancer, the purpose of this study was to assess the reliability of HER2/neu evaluation using this technique in patients with primary breast cancer.
Patients and methods
We investigated the accuracy of immunohistochemical assessment of HER2/neu in core needle biopsies compared with surgically obtained specimens in 325 patients with primary breast cancer. In patients strongly positive for HER2/neu, additional fluorescence in situ hybridization (FISH) analysis of needle biopsies was performed.
Results
Using immunohistochemistry alone, accuracy of HER2/neu assessment in core biopsies in relation to surgically removed specimens was 92% and increased to 96% with additional FISH analysis (weighted Kappa coefficient: 0.86).
Discussion
As proven with this large series of patients, the assessment of HER2/neu status by core needle biopsy in breast cancer is accurate. Notwithstanding, in order to minimize the number of false-positive results, strongly positive core needle biopsies identified using immunohistochemistry should be confirmed by FISH analysis.
References
Jacobs T, Siziopikou K, Prioleau J, Raza S, Baum J, Hayes D, et al (1998) Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor? Mod Pathol 11: 259–264
Harris GC, Denley HE, Pinder SE, Lee AHS, Ellis IO, Elston CW, et al (2003) Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma. Am J Surg Pathol 27: 11–15
Mueller-Holzner E, Fink V, Frede T, Marth C (2001) Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: a reliable predictor of HER2 status of the whole tumor. Breast Cancer Res Treat 69: 13–19
Di Loreto C, Puglisi F, Rimondi G, Zuiani C, Anania G, Della Mea V, et al (1996) Large core biopsy for diagnostic and prognostic evaluation of invasive breast carcinomas. Eur J Cancer 32A: 1693–1700
Connor CS, Tawfik OW, Joyce AJ, Davis MK, Mayo MS, Jewell WR (2002) A comparison of prognostic tumor markers obtained on image-guided breast biopsies and final surgical specimens. Am J Surg 184: 322–324
King CR, Kraus MH, Aaronson SA (1983) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229: 974–976
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al (1989) Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244: 707–712
Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, et al (2001) Letrozole is more effective neodajuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor- positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19: 3808–3816
Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, et al (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p 185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659–2671
Wenzel C, Schmidinger M, Locker GJ, Taucher S, Gnant M, Jakesz R, et al (1999) Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and epidoxorubicin in female breast cancer patients (T1-4, No-2, Mo). Wien Klin Wochenschr 111: 843–850
Bloom H, Richardson W (1957) Histological grading and prognosis in breast cancer. Br J Cancer 11: 359–364
Reiner A, Neumeister B, Spona J, Reiner G, Schemper M, Jakesz R (1990) Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res 50: 7057–7061
Cohen J (1960) A coefficient of agreement for nominal scales. Educational and Psychological Measurement 20: 37–46
Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ (1999) Specificity of Hercep Test in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration-Approved Scoring System. J Clin Oncol 17: 1983–1987
Kaya H, Ragazzini T, Aribal E, Guney I, Kotiloglu E (2001) Her-2/neu gene amplification compared with HER-2/neu protein overexpression on ultrasound guided core-needle biopsy specimens of breast carcinoma. Pathol Oncol Res 7: 279–283
Kaneko S, Gerasimova T, Butler WM, Cupples TE, Guerry PL, Greene GR, et al (2002) The use of FISH on breast core needle samples for the presurgical assessment of HER-2 oncogene status. Exp Mol Pathol 73: 61–66
Thomson TA, Hayes MM, Spinelli JJ, Hilland E, Sawrenko C, Phillips D, et al (2001) HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 14: 1079–1086
Taucher S, Rudas M, Gnant M, Thomanek K, Dubsky P, Roka S, et al (2003) Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer 10: 91–98
Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ (1999) Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 17: 1974–1982
Yamauchi H, Stearns V, Hayes DF (2001) When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19: 2334–2356
Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, et al (2003) Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 16: 173–182
Mitchell MS, Press MF (1999) The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer. Semin Oncol 26: 108–116
Mirza AN, Mirza NQ, Vlastos G, Singletary SE (2002) Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 235: 10–26
Masood S, Bui MM (2002) Prognostic and predictive value of HER2/neu oncogene in breast cancer. Microse Res Tech 59: 102–108
Wenzel C, Schmidinger M, Huber H (2001) Is there progress in chemotherapy for breast cancer? Wien Klin Wochenschr 113: 306–320
Vargas-Roig LM, Gago FE, Tello O, Martin de Civetta MT, Ciocca DR (1999) c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 84: 129–134
Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi MP, Marco BD, et al (1996) Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Res 16: 3105–3110
Schneider J, Lucas R, Sanchez J, Ruibal A, Tejerina A, Martin M (2000) Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDRI and LRP. Anticancer Res 20: 4373–4377
Singletary SE, Atkinson EN, Hoque A, Sneige N, Sahin AA, Fritsche HA Jr, et al (2002) Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin Cancer Res 8: 2835–2842
Rasbridge SA, Gillett CE, Seymour AM, Patel K, Richards MA, Rubens RD, et al (1994) The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 70: 335–341
Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM (2001) Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 19: 2714–2721
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792
Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al (1999) Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 26: 78–83
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Taucher, S., Rudas, M., Mader, R.M. et al. Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer. Wien Klin Wochenschr 116, 26–31 (2004). https://doi.org/10.1007/BF03040420
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03040420